There are about 36818 clinical studies being (or have been) conducted in China. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).
The DCB-ACS trial is a prospective, multi-center, non-inferiority, randomized controlled trail. The purpose of this trial is to evaluate the safety and efficacy of drug-coated balloon(DCB) in de novo lesions for acute coronary syndromes (ACS) .
Aging is a problem that exists in many countries in the world. China has a large population base and a large number of elderly people. Paying attention to the health of the elderly is a problem that the Chinese government and society have been paying attention to. In order to improve the physical fitness of the elderly, the government encourages the elderly to do more exercise. However, the elderly do not exercise usually, and the way of exercise is relatively simple, which cannot meet the needs of comprehensive improvement of the elderly's physical fitness. For example, endurance, strength, flexibility, and balance are the most important to the elderly's physical fitness. Tai Chi Chuan is very popular in China. 79.36% of people in China choose brisk walking as the basic exercise. These two exercises have no venue, equipment requirements, and relatively simple technical movements. They are more convenient for the elderly to implement, and according to the literature It is found that Tai Chi Chaun is very effective in improving the balance and flexibility of the elderly, while brisk walking is very effective in improving endurance, and both Tai Chi and brisk walking can improve the strength of the elderly. Therefore, the combination of Taijiquan and brisk walking in this study can meet the four exercise components of elderly people's comprehensive development of physical fitness, endurance, strength, flexibility, and balance, and through the literature, it is found that the effect of combined exercise is better than that of a single exercise. Therefore, this study is divided into 4 groups, Tai Chi Chuan group, brisk walking group, Tai Chi combination brisk walking group, and control group. The aim of this study is to evaluate the effectiveness of combine brisk walking and Tai Chi Chuan (BWTCC) on health-related physical fitness and selected health parameters among older Chinese women. The specific objectives of these studies are as follows: 1. To evaluate the effectiveness of brisk walking (BW), Tai Chi Chuan (TCC), and their combination (BWTCC) on health-related physical fitness (Cardiorespiratory fitness, Body composition, Flexibility, Muscular Strength, and Muscular endurance) among older Chinese women at pre-test, post-test and at three (3) months post-intervention. 2. To evaluate the effectiveness of brisk walking (BW), Tai Chi Chuan (TCC), and their combination (BWTCC) on health parameters (Blood pressure, Resting heart rate, Balance, Height, and weight) among older Chinese women at pre-test, post-test and at three (3) months post-intervention. 3. To evaluate the effectiveness of brisk walking (BW), Tai Chi Chuan (TCC), and their combination BWTCC on QoL among older Chinese women at pre-test and post-test. The following hypothesis ： HO1: There are no significant differences among the three intervention groups (BW, TCC and BWTCC) and with the control group on health-related physical fitness (Cardiorespiratory fitness, Body composition, Flexibility, Muscular Strength, and Muscular endurance) among older Chinese women at pre-test and post-test. HO2: There are no significant differences among the three intervention groups (BW, TCC and BWTCC) and with the control group on health parameters (Blood pressure, Resting heart rate, Balance) among older Chinese women at pre-test and post-test. HO3: There are no significant differences among the three intervention groups (BW, TCC and BWTCC) and with the control group on QoL among older Chinese women at pre-test and post-test.
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). This study aims to explore whether blockade of Transforming Growth Factor β (TGFβ) in combination with gemcitabine/nab-paclitaxel can reduce fibrosis in PDAC, restore chemo-sensitivity and ultimately lead to improvements in overall survival (OS) and other clinically relevant outcomes.
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in Chinese participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with respect to 1) radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR) and 2) overall survival (OS). As of Amendment 4, the study is being stopped for futility. All the prespecified interim analysis after interim analysis (IA1) and final analysis of the study described the statistical analysis plan (SAP) will not be performed. Safety analysis will be performed at the end of the study; there will be no further analyses for efficacy and electronic patient-reported outcome (ePRO) endpoints collected from participants beyond the IA1 cutoff date. All study participants will stop ongoing treatment with pembrolizumab/placebo. Exceptions may be requested for study participants who, in the assessment of their study physician, are benefitting from the combination of enzalutamide and pembrolizumab, after consulting with the Sponsor. All other study participants should be discontinued from study and be offered standard of care (SOC) treatment as deemed necessary by the Investigator. If enzalutamide as SOC is not accessible off study to the participant, central sourcing may continue. As of Amendment 04, disease progression will no longer be centrally verified, participants will only be assessed locally. As of Amendment 4, Second Course treatment is not an option for participants. There are currently no participants in the Second Course Phase.
The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
There are few clinical trials of chemotherapy combined with immunotherapy in the neoadjuvant stage of locally advanced head and neck squamous cell carcinoma. The "phase II clinical trial of efficacy and safety of immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma" carried out by our team will be an active exploration of the application of immunodrugs in the neoadjuvant stage of newly treated patients with locally advanced head and neck squamous cell carcinoma
The aim of this study was to investigate the added value of Principal Component Regression (PCR) based contrast-enhanced ultrasound (CEUS) for differentiating low risk patients with breast nodules categorized as 4A using the Breast Imaging Reporting and Data System (BI-RADS).
The study is a multicenter, open-label, randomized controlled clinical study, and the purpose of the study is to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with short-term radiotherapy, sequential Camrelizumab and CAPOX (group A) to long-term concurrent chemoradiotherapy, sequential CAPOX (group B) in patients with LARC. A total of 230 patients were included in this study.